anti-Peptidyl Arginine Deiminase, Type IV (PADI4) Antibodies

Human Peptidyl Arginine Deiminase, Type IV (PADI4) interaction partners

1. PADI4 contributes to gastric tumorigenesis by upregulating CXCR2 (show CXCR2 Antibodies), KRT14 (show KRT14 Antibodies) and TNF-alpha (show TNF Antibodies) expression.

2. In this case-control study with sufficient sample size to detect associations, we observed that PADI4 SNPS rs11203367 and rs874881 do not significantly determine RA susceptibility

3. SNPs of PADI4 may be a risk factor for airway abnormalities in RA.

4. this meta-analysis suggested that PADI4 -92C/G polymorphism may be associated with the rheumatoid arthritis incidence in the Chinese population, especially for South China. Further studies conducted on other ethnic groups are required for definite conclusions.

5. PADI4 contributes to the pathogenesis of RA by protecting FLSs from apoptosis. PADI4 suppresses p21 (show CDKN1A Antibodies) transcription through altering histone H3 (show HIST3H3 Antibodies) arginine modifications on p21 (show CDKN1A Antibodies) promoter region.

6. Proteolysis by granzyme B enhances presentation of autoantigenic PAD4 epitopes in rheumatoid arthritis.

7. No associations were found between clinical subtypes of JIA and PADI4 allele frequency. rs2240337 in the PADI4 gene was significantly associated with anti-cyclic citrullinated peptide antibody-positivity in juvenile idiopathic arthritis.

8. The effect of the PADI4-104C/T polymorphism on RA risk in the Chinese population was evaluated in a meta-analysis. The overall analysis indicated a significant association between the PADI4-104C/T polymorphism and RA risk in the Chinese population (T vs C: OR = 1.45, 95%CI = 1.18-1.78; TT vs CC: OR = 1.49, 95%CI = 1.24-1.80; TT vs CC+CT: OR = 1.28, 95%CI = 1.08-1.51; TT+CT vs CC: OR = 1.75, 95%CI = 1.30-2.37).

9. Overexpression of PAD4 constrains the activity of EMT (show ITK Antibodies) via suppressing Elk1 (show ELK1 Antibodies) expression.

10. Our study also demonstrated that PADI4 contributes to tumor metastasis by regulating the gene expression of insulin-like growth factor 1 (IGF1 (show IGF1 Antibodies)) and WAS/WASL-interacting protein family member 1 (WIPF1 (show WIPF1 Antibodies)).

Mouse (Murine) Peptidyl Arginine Deiminase, Type IV (PADI4) interaction partners

1. PADi4 is critical for neutrophil extracellular traps formation, but is dispensable for generalized citrullination

2. sFlt-1 overexpression in Padi4(-/-) mice resulted in dramatically lower inflammatory and thrombotic response, which was accompanied by significant reduction in pregnancy losses. Inhibition of NETosis may serve as a novel target in disorders of impaired placentation.

3. a role for NETs in cardiac fibrosis and conclude that PAD4 regulates age-related organ fibrosis and dysfunction.

4. PADI4 exacerbates arthritis with diverse immunological modifications.

5. Selective inhibition of peptidylarginine deiminase IV with Cl-amidine blocked NET formation, reduced atherosclerotic lesion area, and delayed time to carotid artery thrombosis in a photochemical injury model.

6. Padi4 is part of the pluripotency transcriptional network, binding to regulatory elements of key stem-cell genes and activating their expression

7. PAD4 regulates the proliferation of multipotent progenitors in the bone marrow by controlling c-myc (show MYC Antibodies) expression.

8. PAD4-mediated chromatin decondensation in the neutrophil is crucial for pathological venous thrombosis and present neutrophil activation and PAD4 as potential drug targets for deep vein thrombosis.

9. PAD4 is dispensable in this effector phase model of arthritis

10. analysis of regulation of histone modification and chromatin structure by the p53 (show TP53 Antibodies)-PADI4 pathway